Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 71335-0244

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 71335-0244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350244)

Label for Rabeprazole Sodium delayed-release tablet, 20 mg, repackaged by Bryant Ranch Prepack in Burbank, CA. The label includes the product name, strength, comparison to Aciphex 20 mg tablet by Lannett Company Inc., lot number 1523487, storage instructions at 20°-25°C (68°-77°F), and a barcode. The product is indicated as prescription (RX) only.*

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure diagram of Rabeprazole Sodium, depicting its molecular components including aromatic rings, sulfur, oxygen, sodium atom, and nitrogen atoms as part of its heterocyclic structure.*

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph depicting mean heartburn scores over a 28-day study period comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis shows mean scores ranging from 0 (none) to 4 (very severe). Three lines represent the placebo, 10 mg, and 20 mg doses, showing trends in heartburn severity over time.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

A line graph depicting mean heartburn scores over study days from -14 to 28, comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The y-axis shows mean scores from 0 (none) to 4 (very severe), and the x-axis represents study days. The graph includes a legend for treatment groups and sample sizes.*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph showing mean heartburn scores over a 28-day study period comparing placebo and Rabeprazole Sodium 20 mg treatment groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores, ranging from 0 (none) to 4 (very severe). Separate lines depict score trends for placebo and Rabeprazole Sodium 20 mg groups.*

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (None) to 4 (Very Severe). The Rabeprazole group displays a lower mean heartburn score compared to placebo after day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.